Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)

Dr. Jing X. Li

Holistic Medicine
95 Trade St, Suite 102, 
Aurora, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
95 Trade St, Suite 102, 
Aurora, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jing Li is a Holistic Medicine provider in Aurora, Illinois. Ms. Li is rated as an Advanced provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). Her top areas of expertise are Pancreatic Ductal Adenocarcinoma, Liver Failure, Fractured Spine, Osteotomy, and Endoscopy.

Her clinical research consists of co-authoring 18272 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 14 articles in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Specialties
Holistic Medicine
Licenses
Acupuncturist in IL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

95 Trade St, Suite 102, Aurora, IL 60504

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Using Human Brain Connectivity to Identify the Causal Neuroanatomical Substrate of Depression Symptoms
Using Human Brain Connectivity to Identify the Causal Neuroanatomical Substrate of Depression Symptoms
Enrollment Status: Recruiting
Publish Date: April 21, 2025
Intervention Type: Behavioral, Other
Study Phase: Not Applicable
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD): A Prospective, Multicenter, Randomized, Controlled Trial
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD): A Prospective, Multicenter, Randomized, Controlled Trial
Enrollment Status: Completed
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drugs: Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin
Study Phase: Phase 4
A Prospective Phase III Randomized Trial to Compare Stereotactic Radiosurgery vs. Whole Brain Radiation Therapy for >/= 4 Newly Diagnosed Non-Melanoma Brain Metastases
A Prospective Phase III Randomized Trial to Compare Stereotactic Radiosurgery vs. Whole Brain Radiation Therapy for >/= 4 Newly Diagnosed Non-Melanoma Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Phase II Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases
A Phase II Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 2
Stereotactic Radiosurgery (SRS) as Definitive Management for a Limited Number of Small Cell Lung Cancer (SCLC) Brain Metastasis
Stereotactic Radiosurgery (SRS) as Definitive Management for a Limited Number of Small Cell Lung Cancer (SCLC) Brain Metastasis
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Radiation, Other
Study Phase: Phase 2
A Phase II Clinical Trial Evaluating the Efficacy of Combining Thermal Ablation and Spine Stereotactic Radiosurgery for Patients With Spine Metastases With Moderate to Severe Epidural Involvement
A Phase II Clinical Trial Evaluating the Efficacy of Combining Thermal Ablation and Spine Stereotactic Radiosurgery for Patients With Spine Metastases With Moderate to Severe Epidural Involvement
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2025
Intervention Type: Other, Radiation, Procedure
Study Phase: Phase 2
Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer
Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2025
Intervention Type: Biological, Other, Radiation, Procedure
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: Sitravatinib, Tislelizumab
Study Phase: Phase 1/Phase 2
Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study
Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study
Enrollment Status: Completed
Publish Date: February 04, 2019
Intervention Type: Procedure
A Multi-institutional, Randomized Parallel Controlled, Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Amifostine Every-other-day Regimen and Everyday Regimen From Monday to Friday
A Multi-institutional, Randomized Parallel Controlled, Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Amifostine Every-other-day Regimen and Everyday Regimen From Monday to Friday
Enrollment Status: Unknown
Publish Date: July 13, 2017
Intervention Type: Drug
Study Drug: Amifostine
Study Phase: Phase 2
View 11 Less Clinical Trials

18190 Total Publications

Corrigendum to "Association between the cardiometabolic index and mortality risk in US adults: Data from the National Health and Nutrition Examination Survey (NHANES) 1999-2018" [Journal of Clinical Lipidology (2025) vol 000, 1-8/JACL_2256].
Corrigendum to "Association between the cardiometabolic index and mortality risk in US adults: Data from the National Health and Nutrition Examination Survey (NHANES) 1999-2018" [Journal of Clinical Lipidology (2025) vol 000, 1-8/JACL_2256].
Journal: Journal of clinical lipidology
Published: October 19, 2025
Similar Doctors
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Stanislaw Bryjak
Family Medicine | Holistic Medicine
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Stanislaw Bryjak
Family Medicine | Holistic Medicine

Endeavor Health Medical Group

2739 W Foster Ave, 
Chicago, IL 
 (30.5 miles away)
773-878-8200
Languages Spoken:
English, Polish
See accepted insurances
Accepting New Patients
Offers Telehealth

Stanislaw Bryjak is a Holistic Medicine provider in Chicago, Illinois. Mr. Bryjak is rated as an Experienced provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Heart Failure with Preserved Ejection Fraction (HFpEF), Emphysema, Gallbladder Disease, Ureteroscopy, and Endoscopy. Mr. Bryjak is currently accepting new patients.

Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Roseann E. Brady
Holistic Medicine
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Roseann E. Brady
Holistic Medicine

Roseann Brady, D.O.

110 S Wynstone Park Drive, Suite 101, 
Barrington, IL 
 (27.3 miles away)
224-848-4256
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Roseann Brady is a Holistic Medicine provider in Barrington, Illinois. Ms. Brady is rated as an Experienced provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). Her top areas of expertise are Vitamin D Deficiency, Gallbladder Disease, Sacroiliac Joint Disease, Prostatectomy, and Colonoscopy. Ms. Brady is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Li's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 34 Advanced Conditions
View All 54 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile